Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: An analysis of US population mortality trends and the impact of COVID.

Description: December 8, 2023 - The health insurance industry has historically used several factors to develop premium rates. Many of these, e.g. gender rating, have been largely eliminated from health insurance rating practices by regulations as the Patient Protection and Affordable Care Act (ACA) because they were determined as inequitable.

Description: View the ERMGI Exam Solutions

Description: Zero-Knowledge Proofs (ZKPs) represent an innovative suite of cryptographic algorithms that validate the accuracy of sensitive information without revealing the actual information itself. This report introduces the diverse applications and emerging opportunities that ZKPs offer to the insurance community, especially in the health insurance space.

Description: View the ERMILA Exam Solutions

Description: LIMRA, Reinsurance Group of America (RGA), the Society of Actuaries (SOA) Research Institute, and TAI have collaborated on an ongoing effort to analyze the impact of COVID-19 on the individual life insurance industry’s mortality experience and share the emerging results with the insurance industry and the public. This report contains the results of a cause of death analysis focused on how the rates of death for various causes were impacted throughout the pandemic period through the second quarter of 2022.

Description: Review the ERM Case Study for Fall 2023.

Description: Different mortality projection methodologies are utilized by actuaries across applications and practice areas. As a result, the MIM Advisory Group developed a single framework to serve as a consistent base for practitioners in projecting mortality improvement.

Description: View the ERM Spring 2023 Case Study